177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study

• Published in: Clinical nuclear medicine Vol. 49; no. 9; p. 847
• Main Authors: Mileva, Magdalena, Van Bogaert, Camille, Marin, Gwennaëlle, Danieli, Rachele, Artigas, Carlos, Levillain, Hugo, Ameye, Lieveke, Taraji-Schiltz, Loubna, Stathopoulos, Konstantinos, Wimana, Zéna, Hendlisz, Alain, Flamen, Patrick, Karfis, Ioannis
• Format: Journal Article
• Language: English
• Published: United States 01.09.2024
• Subjects: Adult; Aged; Aged, 80 and over; Female; Humans; Intestinal Neoplasms - radiotherapy; Male; Middle Aged; Neuroendocrine Tumors - radiotherapy; Octreotide - adverse effects; Octreotide - analogs & derivatives; Octreotide - therapeutic use; Organometallic Compounds - adverse effects; Organs at Risk - radiation effects; Pancreatic Neoplasms - diagnostic imaging; Pancreatic Neoplasms - radiotherapy; Prospective Studies; Radiometry; Receptors, Peptide; Safety; Stomach Neoplasms - diagnostic imaging; Stomach Neoplasms - radiotherapy
• ISSN: 1536-0229
• DOI: 10.1097/RLU.0000000000005330

The aim of this study was to assess the association among toxicity, dosimetry of organs-at-risk, and disease progression in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with 177 Lu-DOTATATE. Thirty-seven patients with GEP-NETs underwent 177 Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in a single-arm, prospective, phase 2 study, where patients were followed up with blood tests, isotopic glomerular filtration rate (iGFR), and imaging examinations (CT/MRI and PET) every 6 months until disease progression. Adverse events (AEs) graded per CTCAEv4.03 and occurring during treatment were collected and followed up until resolution. Dosimetry, including biologically effective doses (BEDs) to kidneys, BED to bone marrow, and absorbed dose (AD) to spleen, was performed after each PRRT cycle. Statistical analyses explored associations among dosimetry, toxicity, and patient progression free-survival. The most common AEs were anemia and lymphopenia (65%), followed by thrombocytopenia and fatigue (each 51%), alopecia (46%), and nausea (41%). The most common grade ≥3 AE was lymphopenia (43%). There was no grade ≥3 nephrotoxicity. The median iGFR % decrease was 11% ( P < 0.001), at a median follow-up of 23 months. iGFR %decrease and renal BED did not correlate (Spearman ρ = -0.09). Similarly, no significant association was found between bone marrow BED or spleen AD and the grades of hematological toxicities. We observed no association between progression free-survival and either the decline of renal function or the occurrence of hematological toxicities during PRRT. This study confirms the safety profile of 177 Lu-DOTATATE PRRT in patients with GEP-NETs irrespective of the dosimetry of organs at risk. Kidney, bone marrow, and spleen dosimetry measures were not associated with renal or hematological toxicity.